Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 1.00 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.48 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283848 | 0.93 | LPAR1 (0.87) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL709655 | 0.93 | LPAR1 (0.86) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4031278 | 0.93 | LPAR1 (0.86) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4033529 | 0.92 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030950 | 0.92 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030296 | 0.92 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032482 | 0.92 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032900 | 0.92 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL13385834 | 0.91 | LPAR1 (0.84) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4029310 | 0.90 | LPAR1 (0.82) | LPAR1LPAR3LPAR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20240285587-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2024-08-29 | — | — | US | claimed |
| WO-2024157207-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2024-08-02 | — | — | WO | claimed |
| CN-118340893-A | Application of substance for regulating lysophosphatidic acid receptor 3 in preparation of products for regulating and controlling kidney EPO (EPO) expression | 北京师范大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118055777-A | Novel therapeutic agent for inhibiting metastasis and proliferation of osteosarcoma and glioma | 公益财团法人癌研究会 | 2024-05-17 | — | — | CN | claimed |
| EP-4360650-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | Japanese Foundation For Cancer Research (JP) | 2024-05-01 | — | — | EP | claimed |
| CN-117645970-A | Efficient and rapid acquisition of human pluripotent stem cells by using chemical re-editing method | 广州百康细胞生命科技有限公司 | 2024-03-05 | — | — | CN | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| US-20230390250-A1 | MODULATION OF GLUCAGON-LIKE PEPTIDE 1 AND USES THEREOF | DUNCAN ROBIN ELAINE (CA) | 2023-12-07 | — | — | US | claimed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | claimed |
| CN-115814081-A | Novel inhibitors for blocking viral replication, excessive inflammation and damage to infected organs | 国科大杭州高等研究院 | 2023-03-21 | — | — | CN | claimed |
| WO-2022270621-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | 公益財団法人がん研究会 | 2022-12-29 | — | — | WO | claimed |
| CN-115487299-A | Primary ciliary regulation of biological rhythms and related applications thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-12-20 | — | — | CN | claimed |
| WO-2022087749-A1 | MODULATION OF GLUCAGON-LIKE PEPTIDE 1 AND USES THEREOF | DUNCAN ROBIN ELAINE (CA) | 2022-05-05 | — | — | WO | claimed |
| CN-114306607-A | Primary ciliary regulation of biological rhythms and related applications thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-04-12 | — | — | CN | claimed |
| EP-1364659-B1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| EP-1415667-B1 | PANCREATIC JUICE SECRETION REGULATORS COMPRISING LPA RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO (JP) | 2008-09-03 | — | — | EP | claimed |
| US-6964975-B2 | Isoxazole and thiazole compounds and use thereof as medicine | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | LPAR1 3722/4885LPAR3 3251/4885LPAR2 3733/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | LPAR1 3722/4885LPAR3 3251/4885LPAR2 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.